Reviews
Yaqi Xing, Jiong Yan, Yongdong Niu. PXR: a center of transcriptional regulation in cancer[J]. Acta Pharmaceutica Sinica B, 2020, 10(2): 197-206

PXR: a center of transcriptional regulation in cancer
Yaqi Xinga, Jiong Yanb, Yongdong Niua
a Department of Pharmacology, Shantou University Medical College, Shantou 515041, China;
b Center for Pharmacogenetics, University of Pittsburgh, PA 15261, USA
Abstract:
Pregnane X receptor (PXR, NR1I2) is a prototypical member of the nuclear receptor superfamily. PXR can be activated by both endobiotics and xenobiotics. As a key xenobiotic receptor, the cellular function of PXR is mostly exerted by its binding to the regulatory gene sequences in a liganddependent manner. Classical downstream target genes of PXR participate in xenobiotic responses, such as detoxification, metabolism and inflammation. Emerging evidence also implicates PXR signaling in the processes of apoptosis, cell cycle arrest, proliferation, angiogenesis and oxidative stress, which are closely related to cancer. Here, we discussed, in addition to the characterization of PXR per se, the biological function and regulatory mechanism of PXR signaling in cancer, and its potential for the targeted prevention and therapeutics.
Key words:    PXR    NR1I2    PAR    Signaling    Nuclear receptor    Transcriptional regulation    Cancer   
Received: 2019-01-17     Revised: 2019-06-10
DOI: 10.1016/j.apsb.2019.06.012
Funds: This study was funded by the National Natural Science Foundation of China (81772972 and 81572703); Guangdong Natural Science Foundation (2015A030313449; China); Guangdong Science and Technology Project "Public Research and Capacity Building" Special Project Fund (2014A020212285; China); and Department of Education, Guangdong Government under the Toptier University Development Scheme for Research and Control of Infectious Diseases (2016026, 2015060, and 2015089; China).
Corresponding author: Yongdong Niu     Email:ydniu@126.com
Author description:
Service
PDF(KB) Free
Print
0
Authors
Yaqi Xing
Jiong Yan
Yongdong Niu

References:
1. Oladimeji PO, Chen T. PXR:more than just a master xenobiotic receptor. Mol Pharmacol 2018;93:119-27.
2. Pondugula SR, Mani S. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett 2013;328:1-9.
3. Petryszak R, Keays M, Tang YA, Fonseca NA, Barrera E, Burdett T, et al. Expression Atlas updatedan integrated database of gene and protein expression in humans, animals and plants. Nucleic Acids Res 2016;44:D746-52.
4. Luo W, Xin Y, Zhao X, Zhang F, Liu C, Fan H, et al. Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor. Br J Pharmacol 2017;174:700-17.
5. Mo L, He J. Nuclear hormone receptors PXR and CAR and metabolic diseases. Horm Mol Biol Clin Investig 2014;19:129-40.
6. He J, Nishida S, Xu M, Makishima M, Xie W. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts. Gastroenterology 2011;140:2095-106.
7. Noreault TL, Kostrubsky VE, Wood SG, Nichols RC, Strom SC, Trask HW, et al. Arsenite decreases CYP3A4 and RXRa in primary human hepatocytes. Drug Metab Dispos 2005;33:993-1003.
8. Campa D, Butterbach K, Slager SL, Skibola CF, de Sanjose S, Benavente Y, et al. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer 2012;131:803-12.
9. Melis M, Diaz G, Kleiner DE, Zamboni F, Kabat J, Lai J, et al. Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J Transl Med 2014;12:230.
10. Nittke T, Selig S, Kallay E, Cross HS. Nutritional calcium modulates colonic expression of vitamin D receptor and pregnane X receptor target genes. Mol Nutr Food Res 2008;52 Suppl 1:S45-51.
11. Mbatchi LC, Robert J, Ychou M, Boyer JC, Del Rio M, Gassiot M, et al. Effect of single nucleotide polymorphisms in the xenobioticsensing receptors NR1I2 and NR1I3 on the pharmacokinetics and toxicity of Irinotecan in colorectal cancer patients. Clin Pharmacokinet 2016;55:1145-57.
12. Abbas Sascha. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 2010;126:2935-46.
13. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-45.
14. Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metabol 2005;6:357-67.
15. Sepe V, D'Amore C, Ummarino R, Renga B, D'Auria MV, Novellino E, et al. Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges. Eur J Med Chem 2014;73:126-34.
16. Noble SM, Carnahan VE, Moore LB, Luntz T, Wang H, Ittoop OR, et al. Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 2006;45:8579-89.
17. Cui JY, Gunewardena SS, Rockwell CE, Klaassen CD. ChIPing the cistrome of PXR in mouse liver. Nucleic Acids Res 2010;38:7943-63.
18. Rana M, Dash AK, Ponnusamy K, Tyagi RK. Nuclear localization signal region in nuclear receptor PXR governs the receptor association with mitotic chromatin. Chromosome Res 2018;26:255-76.
19. Jeske J, Bitter A, Thasler WE, Weiss TS, Schwab M, Burk O. Liganddependent and -independent regulation of human hepatic sphingomyelin phosphodiesterase acid-like 3A expression by pregnane X receptor and crosstalk with liver X receptor. Biochem Pharmacol 2017;136:122-35.
20. Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis 2012;33:2311-9.
21. Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, et al. Characterization of a novel PXR isoform with potential dominant-negative properties. J Hepatol 2014;61:609-16.
22. Jonker JW, Liddle C, Downes M. FXR and PXR:potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 2012;130:147-58.
23. Mackowiak B, Hodge J, Stern S, Wang H. The roles of xenobiotic receptors:beyond chemical disposition. Drug Metab Dispos 2018;46:1361-71.
24. di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR:molecular, functional, and biomedical aspects. Mol Asp Med 2009;30:297-343.
25. Uppal H, Toma D, Saini SP, Ren S, Jones TJ, Xie W. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 2005;41:168-76.
26. Banerjee M, Robbins D, Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today 2015;20:618-28.
27. Butenhoff JL, Chang SC, Olsen GW, Thomford PJ. Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonateinSpragueDawleyrats.Toxicology2012;293:1-15.
28. Cocci P, Mosconi G, Palermo FA. Pregnane X receptor (PXR) signaling in seabream primary hepatocytes exposed to extracts of seawater samples collected from polycyclic aromatic hydrocarbons (PAHs)-contaminated coastal areas. Mar Environ Res 2017;130:181-6.
29. Kumar S, Jaiswal B, Kumar S, Negi S, Tyagi RK. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Biochem Pharmacol 2010;80:964-76.
30. Li J, Zhao J, Wang H, Li X, Liu A, Qin Q, et al. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. OncoTargets Ther 2018;11:5885-94.
31. Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, Flockhart DA, et al. In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4a expression. Drug Metab Dispos 2012;40:726-33.
32. Smutny T, Mani S, Pavek P. Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metabol 2013;14:1059-69.
33. Wei Z, Chen M, Zhang Y, Wang X, Jiang S, Wang Y, et al. No correlation of hsa-miR-148a with expression of PXR or CYP3A4 in human livers from Chinese Han population. PLoS One 2013;8. e59141.
34. Revathidevi S, Sudesh R, Vaishnavi V, Kaliyanasundaram M, MaryHelen KG, Sukanya G, et al. Screening for the 3'UTR polymorphism of the PXR gene in South Indian breast cancer patients and its potential role in pharmacogenomics. Asian Pac J Cancer Prev APJCP 2016;17:3971-7.
35. Dempsey JL, Cui JY. Regulation of hepatic long noncoding RNAs by pregnane X receptor and constitutive androstane receptor agonists in mouse liver. Drug Metab Dispos 2019;47:329-39.
36. Brewer CT, Chen T. PXR variants:the impact on drug metabolism and therapeutic responses. Acta Pharm Sin B 2016;6:441-9.
37. Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, et al. ETS-1 induces sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res 2018;135:188-200.
38. Oladimeji PO, Wright WC, Wu J, Chen T. RNA interference screen identifies NAA10 as a regulator of PXR transcription. Biochem Pharmacol 2019;160:92-109.
39. Wang C, Xu W, Zhang Y, Huang D, Huang K. Poly(ADP-ribosyl)ated PXR is a critical regulator of acetaminophen-induced hepatotoxicity. Cell Death Dis 2018;9:819.
40. Pasquel D, Doricakova A, Li H, Kortagere S, Krasowski MD, Biswas A, et al. Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity. Biochim Biophys Acta 2016;1859:1155-69.
41. Bakshi K, Ranjitha B, Dubey S, Jagannadham J, Jaiswal B, Gupta A. Novel complex of HAT protein TIP60 and nuclear receptor PXR promotes cell migration and adhesion. Sci Rep 2017;7:3635.
42. Cui W, Sun M, Zhang S, Shen X, Galeva N, Williams TD, et al. A SUMO-acetyl switch in PXR biology. Biochim Biophys Acta 2016; 1859:1170-82.
43. Priyanka Kotiya D, Rana M, Subbarao N, Puri N, Tyagi RK. Transcription regulation of nuclear receptor PXR:role of SUMO-1 modification and NDSM in receptor function. Mol Cell Endocrinol 2016;420:194-207.
44. Sugatani J, Uchida T, Kurosawa M, Yamaguchi M, Yamazaki Y, Ikari A, et al. Regulation of pregnane X receptor (PXR) function and UGT1A1 gene expression by posttranslational modification of PXR protein. Drug Metab Dispos 2012;40:2031-40.
45. Pondugula SR, Dong H, Chen T. Phosphorylation and proteineprotein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metabol Toxicol 2009;5:861-73.
46. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014:mutations, PTMs and recalibrations. Nucleic Acids Res 2015;43:D512-20.
47. Smutny T, Bitman M, Urban M, Dubecka M, Vrzal R, Dvorak Z, et al. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells. Arch Toxicol 2014;88:2243-59.
48. Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1:establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther 2018;104:1182-90.
49. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013;19:418-20.
50. Brigelius-Flohe R. Induction of drug metabolizing enzymes by vitamin E. J Plant Physiol 2005;162:797-802.
51. Zhou J, Liu M, Zhai Y, Xie W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol 2008;22:868-80.
52. Lin W, Wang YM, Chai SC, Lv L, Zheng J, Wu J, et al. SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 2017;8:741.
53. Sui Y, Park SH, Wang F, Zhou C. Perinatal bisphenol A exposure increases atherosclerosis in adult male PXR-humanized mice. Endocrinology 2018;159:1595-608.
54. Motta S, Callea L, Giani Tagliabue S, Bonati L. Exploring the PXR ligand binding mechanism with advanced molecular dynamics methods. Sci Rep 2018;8:16207.
55. Shichiri M, Fukai N, Kono Y, Tanaka Y. Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. Cancer Res 2009;69:4760-8.
56. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322:391-8.
57. Hassani-Nezhad-Gashti F, Rysa J, Kummu O, Napankangas J, Buler M, Karpale M, et al. Activation of nuclear receptor PXR impairs glucose tolerance and dysregulates GLUT2 expression and subcellular localization in liver. Biochem Pharmacol 2018;148:253-64.
58. Krausova L, Stejskalova L, Wang H, Vrzal R, Dvorak Z, Mani S, et al. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 2011;82:1771-80.
59. Mani S, Huang H, Sundarababu S, Liu W, Kalpana G, Smith AB, et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 2005;11:6359-69.
60. Wang C, Huo XK, Luan ZL, Cao F, Tian XG, Zhao XY, et al. Alismanin A, a triterpenoid with a C34 skeleton from Alisma orientale as a natural agonist of human pregnane X Receptor. Org Lett 2017;19:5645-8.
61. Wang L, Li F, Lu J, Li G, Li D, Zhong XB, et al. The Chinese herbal medicine Sophora flavescens activates pregnane X receptor. Drug Metab Dispos 2010;38:2226-31.
62. Moscovitz JE, Kalgutkar AS, Nulick K, Johnson N, Lin Z, Goosen TC, et al. Establishing tanscriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes. J Pharmacol Exp Ther 2018;365:262-71.
63. Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistle's active components silybin and isosilybin:novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab Dispos 2013;41:1494-504.
64. Hodnik Z, Peterlin Masic L, Tomasic T, Smodis D, D'Amore C, Fiorucci S, et al. Bazedoxifene-scaffold-based mimetics of solomonsterols A and B as novel pregnane X receptor antagonists. J Med Chem 2014;57:4819-33.
65. Pavek P. Pregnane X Receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions. Front Pharmacol 2016;7:456.
66. Li CW, Dinh GK, Chen JD. Preferential physical and functional interaction of pregnane X receptor with the SMRTa isoform. Mol Pharmacol 2009;75:363-73.
67. Niu Y, Wu Z, Shen Q, Song J, Luo Q, You H, et al. Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis 2013;45:1041-8.
68. Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor:from bench to bedside. Expert Opin Drug Metabol Toxicol 2008;4:895-908.
69. Dong Y, Wang Z, Xie GF, Li C, Zuo WW, Meng G, et al. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistancerelated protein 3 in colorectal cancer. Mol Cancer 2017;16:71.
70. Satyanarayana R, Pondugula PP, Mani Sridhar. Pregnane X receptor and cancer:context-specificity is key. Nucl Recept Res 2016;12:3.
71. Oetjen LK, Trier AM, Kim BS. PXR:a new player in atopic dermatitis. J Investig Dermatol 2018;138:8-10.
72. Zhu H, Chen Z, Ma Z, Tan H, Xiao C, Tang X, et al. Tanshinone IIA protects endothelial cells from H2O2-induced injuries via PXR activation. Biomol Ther (Seoul) 2017;25:599-608.
73. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drugedrug interactions in oncology. Cancer Treat Rev 2007;33:369-80.
74. Kotiya D, Jaiswal B, Ghose S, Kaul R, Datta K, Tyagi RK. Role of PXR in hepatic cancer:its influences on liver detoxification capacity and cancer progression. PLoS One 2016;11. e0164087.
75. Ku P, Wang C, Nie X, Ou R, Li K. Regulation of pregnane-X-receptor and microRNAs on detoxification-related genes expressions in Mugilogobius abei under the exposure to diclofenac. Environ Pollut 2018;233:395-406.
76. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2007;14:293-303.
77. Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol 2018;19:1319-29.
78. Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, et al. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Canc 2010;102:1753-61.
79. Niu Y, Wang Z, Huang H, Zhong S, Cai W, Xie Y, et al. Activated pregnane X receptor inhibits cervical cancer cell proliferation and tumorigenicity by inducing G2/M cell-cycle arrest. Cancer Lett 2014; 347:88-97.
80. Huang K, Mukherjee S, DesMarais V, Albanese JM, Rafti E, Draghi Ii A, et al. Targeting the PXReTLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. Pediatr Res 2018;83:1031-40.
81. Malekshah OM, Lage H, Bahrami AR, Afshari JT, Behravan J. PXR and NF-kB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci 2012; 47:474-80.
82. Wahli W. A gut feeling of the PXR, PPAR and NF-kB connection. J Intern Med 2008;263:613-9.
83. Ning R, Zhan Y, He S, Hu J, Zhu Z, Hu G, et al. Interleukin-6 induces DEC1, promotes DEC1 interaction with RXRa and suppresses the expression of PXR, CAR and their target genes. Front Pharmacol 2017;8:866.
84. Zhou T, You WT, Ma ZC, Liang QD, Tan HL, Xiao CR, et al. Ginkgolide B protects human umbilical vein endothelial cells against xenobiotic injuries via PXR activation. Acta Pharmacol Sin 2016;37:177-86.
85. Shehu AI, Lu J, Wang P, Zhu J, Wang Y, Yang D, et al. Pregnane X receptor activation potentiates ritonavir hepatotoxicity. J Clin Investig 2019;129:2898-903.
86. Xie Y, Xu M, Deng M, Li Z, Wang P, Ren S, et al. Activation of pregnane X peceptor sensitizes mice to hemorrhagic shock induced liver injury. Hepatology 2019. Available from:https://doi.org/10.1002/hep.30691.
87. Esposito G, Gigli S, Seguella L, Nobile N, D'Alessandro A, Pesce M, et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol 2016;49:639-45.
88. Cheng J, Fang ZZ, Nagaoka K, Okamoto M, Qu A, Tanaka N, et al. Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer. J Pharmacol Exp Ther 2014;351:559-67.
89. Shichiri M, Tanaka Y. Inhibition of cancer progression by rifampicin:involvement of antiangiogenic and anti-tumor effects. Cell Cycle 2010;9:64-8.
Similar articles:
1.Christin P. Hollis, Alan K. Dozier, Barbara L. Knutson, Tonglei Li.Preparation and characterization of multimodal hybrid organic and inorganic nanocrystals of camptothecin and gold[J]. Acta Pharmaceutica Sinica B, 2019,9(1): 128-134
2.Xusheng Wang, Haiyan Chen, Xiaowei Zeng, Wenpeng Guo, Yu Jin, Shan Wang, Ruiyun Tian, Yanjiang Han, Ling Guo, Jimin Han, Yaojiong Wu, Lin Mei.Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system[J]. Acta Pharmaceutica Sinica B, 2019,9(1): 167-176
3.Lu Zhong, Lu Xu, Yanying Liu, Qingsong Li, Dongyang Zhao, Zhenbao Li, Huicong Zhang, Haotian Zhang, Qiming Kan, Yongjun Wang, Jin Sun, Zhonggui He.Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy[J]. Acta Pharmaceutica Sinica B, 2019,9(2): 397-409
4.Qin Guo, Chao Li, Wenxi Zhou, Xinli Chen, Yu Zhang, Yifei Lu, Yujie Zhang, Qinjun Chen, Donghui Liang, Tao Sun, Chen Jiang.GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy[J]. Acta Pharmaceutica Sinica B, 2019,9(4): 832-842
5.Yukun Huang, Xiaoling Gao, Jun Chen.Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy[J]. Acta Pharmaceutica Sinica B, 2018,8(1): 4-13
6.Ruixiang Li, Yuwei He, Shuya Zhang, Jing Qin, Jianxin Wang.Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment[J]. Acta Pharmaceutica Sinica B, 2018,8(1): 14-22
7.Yixian Zhou, Guilan Quan, Qiaoli Wu, Xiaoxu Zhang, Boyi Niu, Biyuan Wu, Ying Huang, Xin Pan, Chuanbin Wu.Mesoporous silica nanoparticles for drug and gene delivery[J]. Acta Pharmaceutica Sinica B, 2018,8(2): 165-177
8.Yangyang Li, Qiaolin Wei, Fei Ma, Xin Li, Fengyong Liu, Min Zhou.Surface-enhanced Raman nanoparticles for tumor theranostics applications[J]. Acta Pharmaceutica Sinica B, 2018,8(3): 349-359
9.Xiao-Mei Qi, Fang Wang, Matthew Mortensen, Ryan Wertz, Guan Chen.Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy[J]. Acta Pharmaceutica Sinica B, 2018,8(4): 511-517
10.Pallabita Chowdhury, Prashanth K. B. Nagesh, Sheema Khan, Bilal B. Hafeez, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu.Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer[J]. Acta Pharmaceutica Sinica B, 2018,8(4): 602-614
11.Lifei Zhu, Miao Li, Xiaoyan Liu, Lina Du, Yiguang Jin.Inhalable oridonin-loaded poly(lactic-co-glycolic) acid large porous microparticles for in situ treatment of primary non-small cell lung cancer[J]. Acta Pharmaceutica Sinica B, 2017,7(1): 80-90
12.Xinli Chen, Lisha Liu, Chen Jiang.Charge-reversal nanoparticles: novel targeted drug delivery carriers[J]. Acta Pharmaceutica Sinica B, 2016,6(4): 261-267
13.Eun Ji Hong, Dae Gun Choi, Min Suk Shim.Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials[J]. Acta Pharmaceutica Sinica B, 2016,6(4): 297-307